[
    [
        {
            "time": "2018-01-02",
            "original_text": "Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan",
            "features": {
                "keywords": [
                    "consumer groups",
                    "unions",
                    "caution",
                    "AbbVie",
                    "Allergan",
                    "deal"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Gilead Tops List of Most Innovative Drug Companies",
            "features": {
                "keywords": [
                    "Gilead",
                    "innovative",
                    "drug companies"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Gilead Tops List of Most Innovative Drug Companies",
                "Correlation": 2,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade",
            "features": {
                "keywords": [
                    "Humira",
                    "sales",
                    "crash",
                    "AbbVie",
                    "upgrade"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Buy AbbVie Stock, Because Its Deal for Allergan Just Might Work, Analyst Says",
            "features": {
                "keywords": [
                    "buy",
                    "AbbVie",
                    "stock",
                    "deal",
                    "Allergan",
                    "analyst"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Buy AbbVie Stock, Because Its Deal for Allergan Just Might Work, Analyst Says",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie Stock Rises After UBS Upgrades To Buy",
            "features": {
                "keywords": [
                    "AbbVie",
                    "stock",
                    "rises",
                    "UBS",
                    "upgrades",
                    "buy"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Stock Rises After UBS Upgrades To Buy",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Anxious About AbbVie? Here Are 4 Things You Should Know",
            "features": {
                "keywords": [
                    "anxious",
                    "AbbVie",
                    "things",
                    "know"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Anxious About AbbVie? Here Are 4 Things You Should Know",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]